XLR-12
XLR-12 is an indole-based synthetic cannabinoid drug that was invented by Abbott Laboratories in 2006.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
XLR-12 is an indole-based synthetic cannabinoid drug that was invented by Abbott Laboratories in 2006. It is an analogue of XLR-11 where the 5-fluoropentyl chain has been replaced with a 4,4,4-trifluorobutyl chain. XLR-12 is relatively highly selective for the CB 2 receptor, with a K i of 0.09 nM and 167x selectivity over the related CB 1 receptor, however it still retains appreciable affinity for CB 1 with a K i of 15 nM.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1332233314 under CC BY-SA 4.0; modifications have been made.